NAMS
NewAmsterdam Pharma Company N.V.
$29.72
-$1.74(-5.53%)
51
Overall
50
Value
50
Tech
55
Quality
Market Cap
$3.96B
Volume
1.00M
52W Range
$15.82 - $42.00
Target Price
$49.92
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $102.7M | $14.1M | $45.6M | $22.5M | ||
| Total Revenue | $102.7M | $14.1M | $45.6M | $22.5M | ||
| GROSS PROFIT | ||||||
| Gross Profit | $102.7M | $14.1M | $45.6M | $22.5M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $106.3M | $197.1M | $221.9M | $248.2M | ||
| Research & Development | $86.7M | $159.4M | $151.4M | $141.8M | ||
| Research Expense | $86.7M | $159.4M | $151.4M | $141.8M | ||
| Selling, General & Administrative | $19.5M | $37.6M | $70.4M | $106.4M | ||
| Selling & Marketing Expenses | $5.5M | -- | -- | -- | ||
| General & Administrative Expenses | $19.5M | $37.6M | $70.4M | $106.4M | ||
| Salaries & Wages | $4.2M | $24.6M | $33.6M | $59.4M | ||
| Depreciation & Amortization | $72.0K | -- | -- | -- | ||
| Depreciation & Amortization | $72.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-3.6M | $-183.0M | $-176.3M | $-225.7M | ||
| EBITDA | $-22.3M | $-176.9M | $-241.7M | $-205.0M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $287.0K | -- | -- | -- | ||
| Intinc | $11.0K | $11.3M | $16.9M | $27.6M | ||
| Net Non-Operating Interest Income/Expense | $-287.0K | $11.3M | $16.9M | $27.6M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-22.3M | $-176.9M | $-241.6M | $-203.8M | ||
| Pre-Tax Income | $-22.6M | $-176.9M | $-241.6M | $-203.8M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | $27.0K | $-1.0K | -- | ||
| NET INCOME | ||||||
| Net Income | $-22.6M | $-176.9M | $-241.6M | $-203.8M | ||
| Net Income (Continuing Operations) | $-22.6M | $-176.9M | $-241.6M | $-203.8M | ||
| Net Income (Discontinued Operations) | $-22.6M | $-176.9M | $-241.6M | $-203.8M | ||
| Net Income (Common Stockholders) | $-22.6M | $-176.9M | $-241.6M | $-203.8M | ||
| Normalized Income | $-17.9M | -- | $-241.6M | $-201.8M | ||
| TOTALS | ||||||
| Total Expenses | $106.3M | $197.1M | $221.9M | $248.2M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $81.3M | $82.3M | $101.3M | $118.5M | ||
| Average Shares Outstanding (Diluted) | $81.3M | $82.3M | $36.0M | $118.5M | ||
| Shares Outstanding | $81.6M | $89.3M | $109.8M | $115.0M | ||
| Basic EPS | $-0.96 | $-2.15 | $-2.56 | $-1.72 | ||
| Basic EPS (Continuing Operations) | $-0.96 | $-2.15 | $-2.56 | $-1.72 | ||
| Diluted EPS | $-0.96 | $-2.15 | $-2.56 | $-1.72 | ||
| Diluted EPS (Continuing Operations) | $-0.96 | $-2.15 | $-2.56 | $-1.72 | ||
| OTHER METRICS | ||||||
| Commission Expenses | $2.5M | -- | -- | -- | ||
| Fees | $-271.0K | -- | -- | -- | ||
| Insurance And Claims | $289.0K | -- | -- | -- | ||
| Other Gand A | $19.5M | $37.6M | $70.4M | $106.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $29.72 | -5.5% | 1.00M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW